Anterogen.Co.Ltd
Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regen… Read more
Anterogen.Co.Ltd (065660) - Total Liabilities
Latest total liabilities as of September 2025: ₩1.40 Billion KRW
Based on the latest financial reports, Anterogen.Co.Ltd (065660) has total liabilities worth ₩1.40 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anterogen.Co.Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Anterogen.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Anterogen.Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Anterogen.Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Immobiliare Grande Distribuzione SIIQ SpA
LSE:0STP
|
UK | €1.26 Billion |
|
Yanlord Land Group Limited
PINK:YLDGF
|
USA | $66.13 Billion |
|
Wuhan Xingtu Xinke Electronics Co Ltd
SHG:688081
|
China | CN¥164.84 Million |
|
Arnoldo Mondadori Editore S.p.A.
LSE:0KAV
|
UK | €815.67 Million |
|
Hubei Forbon Technology Co Ltd
SHE:300387
|
China | CN¥502.10 Million |
|
Blackline Safety Corp
PINK:BLKLF
|
USA | $88.33 Million |
|
Orient Electric Limited
NSE:ORIENTELEC
|
India | ₹7.46 Billion |
|
Tianjin Hi-Tech Development Co Ltd
SHG:600082
|
China | CN¥1.24 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Anterogen.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 41.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anterogen.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anterogen.Co.Ltd (2014–2024)
The table below shows the annual total liabilities of Anterogen.Co.Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩5.87 Billion | -70.65% |
| 2023-12-31 | ₩19.99 Billion | +15.25% |
| 2022-12-31 | ₩17.34 Billion | -12.57% |
| 2021-12-31 | ₩19.83 Billion | +50.98% |
| 2020-12-31 | ₩13.14 Billion | -18.91% |
| 2019-12-31 | ₩16.20 Billion | -64.29% |
| 2018-12-31 | ₩45.37 Billion | +293.48% |
| 2017-12-31 | ₩11.53 Billion | +721.17% |
| 2016-12-31 | ₩1.40 Billion | -24.04% |
| 2015-12-31 | ₩1.85 Billion | +22.79% |
| 2014-12-31 | ₩1.51 Billion | -- |